Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)

Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.

Uloženo v:
Podrobná bibliografie
Vydáno v:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Ročník 16; číslo 4; s. S30 - S31
Hlavní autoři: Ozaka, Masato, Ishii, Hiroshi, Sato, Tosiya, Ueno, Makoto, Ikeda, Masafumi, Uesugi, Kazuhiro, Sata, Naohiro, Miyashita, Kouichirou, Mizuno, Nobumasa, Tsuji, Kunihiro, Okusaka, Takuji, Furuse, Junji
Médium: Journal Article
Jazyk:angličtina
Vydáno: Philadelphia Elsevier B.V 01.08.2016
Elsevier Limited
Témata:
Chemotherapy
Confidence intervals
Endocrinology & Metabolism
Gastroenterology and Hepatology
Metastasis
Neutropenia
Pancreatic cancer
ISSN:1424-3903, 1424-3911
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2016.06.120